Webinar: The Making of Recombinant Anti-idiotypic Antibodies for High Performance in Bioanalytical Assays

Follow us on:

Facebook X Linkedin YouTube Pinterest WeChat

Do you spend time generating, selecting and qualifying antibodies for development of bioanalytical assays?

Critical reagents, such as antibodies, directly impact the quality and reproducibility of ligand binding assays and consequently could lead to inaccurate conclusions and delay the drug development process if they are of poor quality. If you have confidence in the antibodies you select, you can ensure optimal assay performance over time and generate accurate, trustworthy results.

In this webinar we describe how Bio-Rad develops highly specific, high affinity recombinant monoclonal anti-idiotypic antibodies ideal for use in PK and ADA assays.

We show how these antibodies are made using the HuCAL® antibody library and phage display technology, how they can be used in PK assays to detect free drug and total drug, and also their use as a reference standard in ADA bridging ELISAs. Additionally, the thorough characterization and quality control process is explained, demonstrating how these antibodies facilitate the development of robust and reproducible bioanalytical assays.

Webinar: The making of recombinant anti-idiotypic antibodies for high performance in bioanalytical assays

Presented by: Dr Christian Frisch, R&D Manager at Bio-Rad Laboratories

Speaker Biography:

Dr Christian Frisch, R&D Manager at Bio-Rad Laboratories Christian Frisch is R&D manager at Bio-Rad and has led the antibody generation group since 2003. He studied molecular biology in Göttingen (Germany) and did his Ph.D. with Prof. Alan Fersht at the University of Cambridge (UK) working on the energetics of protein-protein interactions and protein folding. In 1997 he joined MorphoSys AG, working on the development of display technologies and the generation of antibody phage display libraries. His group at Bio-Rad has generated more than 25,000 antibodies for custom projects over the last 13 years.